Study	Reason for exclusion
Adami 1994	Not a randomised clinical study. Study without a comparison of interest. The study compared alendronate (20 mg or 40 mg daily) for 3 to 6 months
Adami 2002	Randomised clinical study. Study without a comparison of interest. The study compared three doses of neridronate (12.5 mg, 25 mg, 50 mg or 100 mg daily for two consecutive days)
Altman 1985	Not a randomised clinical study. Study without a comparison of interest. The study describes the outcomes in a series of participants treated with different regimes of oral Etidronate (5 mg/kg daily for 6 months, 10 mg/kg daily for 3 months, or 20 mg/kg daily for 3 moths).
Arlot 1981	Not a randomised clinical study. Study without an outcome of interest. The study was designed to analyse the effect of different doses of Etidronate (5 mg/kg or 20 mg/kg for 6 months) or clodronate (400 mg/day or 1600 mg/day for 6 months) over the serum acid level.
Atkins 1987	Not a randomised clinical study. Study without a comparison of interest. The study compares three doses of the Neridronate (400 mg oral for one month, 25 mg daily infusion for 5 days and 50 mg daily infusion for 5 days).
Buckler 1998	Randomised clinical study. Study without a comparison of interest. The study compared two regimes of administration of pamidronate (initial 30 mg infusion followed by three infusion of 60 mg and a final placebo infusion at fortnightly intervals or initial placebo infusion followed by three infusion of 60 mg and a final 30 mg infusion at fortnightly intervals), with the same total dose (210 mg).
Cundy 2016	Not a randomised clinical study. Study without a comparison of interest. The study shows data from a cohort of 107 elderly participants (mean age 76 years) treated with intravenous zoledronate followed‐up for 10 years.
Delmas 1982	Randomised clinical study. Study without a comparison of interest. The study compared four doses of clodronate (400, 800, 1600 or 2400 mg daily), with (the four doses) or without (only 400 and 1600 mg doses) vitamin D and calcium supplementation (elemental calcium 1g/day and vitamin D2 8000 IU/day).
Devogelaer 1997	Data on a sample of participants diagnosed with Paget's disease of bone from a randomised clinical trial (Roux 1995). The study was designed to analyse radiological changes during treatment with bisphosphonates.
Devogelaer 2014	Not a randomised clinical study. Study without a comparison of interest. Data from the Belgian Paget's Disease Registry of patients diagnosed as Paget's disease of bone and treated with a 5 mg intravenous infusion of zoledronate.
Dewis 1985	Not a randomised clinical study. Study with a comparison of interest. "Open trial" (9 participants were randomised and 8 participants were put directly into one of the two treatment groups) comparing the effectiveness of two bisphosphonates (etidronate 20 mg/kg once daily for 3 months vs. pamidronate 4 to 5 mg/kg twice daily for 3 months).
Donáth 2004	Case‐control study. Study without a comparison of interest. Cases were patients diagnosed as Paget's disease of bone with temporal bone involvement. Control were healthy individuals matched for age and sex. The study was designed to analyse the effectiveness of two bisphosphonates (pamidronate 30 mg daily infusion for 6 days or oral tiludronate 400 mg daily for 3 months). The study included audiometric assessment and hearing threshold examination.
Filipponi 1994	Not a randomised clinical study. Study with a comparison of interest. The study compares the effectiveness of two bisphosphonates (Clodronate 300 mg/daily intravenous infusion for 5 consecutive days vs. Alendronate 5 mg/ daily intravenous infusion for 5 consecutive days).
Gallacher 1991	Not a randomised clinical study. Study without a comparison of interest. The study compares three regimes of administration of pamidronate, two with a total dose of 180 mg (30 mg weekly infusions for 6 weeks or 45 mg infusions every 3 months for one year) and one with a total dose of 360 mg (30 mg weekly infusions for 6 weeks and 60 mg weekly infusions for three additional weeks). A random subgroup of 6 participants were given placebo infusions of 0.9% saline weekly for three weeks at the start of treatment in a single‐blind study in the group of 30 mg weekly doses for 6 weeks (data are not shown on manuscript).
Garnero 1998	Data on a sample of participants diagnosed as Paget's disease of bone from a randomised clinical trial, and a case‐control study. For the case‐control study, cases were selected from three of five groups of a clinical trial on Paget's disease of bone (Schaffer 1996). Controls were healthy individuals matched for age and sex. The clinical trial included the cases and was designed to analyse the effect of zoledronate on bone turnover markers.
Garnero 2001	Data on a sample of participants diagnosed with Paget's disease of bone from a randomised clinical trial and a case‐control study (selected from a clinical trial on Paget's disease of bone, Schaffer 1996). Controls were healthy age‐matched individuals. The clinical trial included the cases and was designed to analyse the effect of zoledronate on bone turnover markers
Goldman 1975	Data from a sample of participants diagnosed with Paget's disease of bone from a randomised clinical trial (Altman 1973). The study was designed to assess the changes in radionuclide uptake after bisphosphonate treatment
Grauer 1999	Not a randomised clinical study. Study without a comparison of interest. The study compared three different doses of ibandronate (2 mg, 4 mg or 6 mg intravenous infusions) for re‐treatment of participants previously treated with ibandronate after biochemical relapse (increase of alkaline phosphatase).
Gutteridge 1996	Not a randomised clinical study. Study without a comparison of interest. The study compared three different doses of pamidronate. Participation allocation had two steps: three groups according to index of bone resorption (urinary hydroxyproline x plasma creatinine/urinary creatinine). The higher the index (< 5, 5 to 9.99, ≥ 10), the higher the pamidronate dose (120 mg, 180 mg, 240 mg). The three groups were then randomised to two subgroups; total dose in 30 mg infusions or total dose in 60 mg infusions
Hooper 2009	Randomised clinical study. Study without a comparison of interest. The study compared administration of alendronate 280 mg weekly vs. 40 mg daily for 6 months
Hosking 1976	Not a randomised clinical study. Study without a comparison of interest. The study compared administration of etidronate (7.5 mg/kg or 15 mg/kg daily and etidronate plus calcitonin simultaneously (etidronate 7.5 mg/kg daily together with calcitonin 0.5 mg once daily subcutaneous for 6 months) or sequentially (etidronate 15 mg/kg daily for 6 months followed by calcitonin 0.5 mg twice daily subcutaneous for 6 months)
Khairi 1974	Extension study (Altman 1973) with a non‐randomised crossover design. The groups from the original study (placebo and etidronate doses of 1 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg) were reassigned to different doses of etidronate for six additional months. Participants from placebo and 1 mg/kg and 2.5 mg/kg groups were reassigned to etidronate on doses of 5 mg/kg, 10 mg/kg or 20 mg/kg. Participants from the 5 mg/kg group were kept on the same dose. Participants from the 10 mg/kg or 20 mg/kg groups were reassigned to placebo or to remain on the same etidronate dose
Khairi 1977	Not a randomised clinical study. Study without a comparison of interest. Data from a cohort of participants diagnosed with Paget's disease of bone who were treated with etidronate; 60/116 participants took part in a previous study (Khairi 1974)
Khan 1997	Randomised clinical study. Study without a comparison of interest. The study compared different doses (40 or 80 mg/daily) and regimens (3 or 6 months) of oral alendronate
Lombardi 1999	Review. Compilation of the results of two RCTs on alendronate for Paget's disease of bone (Reid 1996 and Siris 1996).
Mazeries 1996	Not a randomised clinical study. Study without a comparison of interest. The study compared two regimens of pamidronate infusion (1 infusion of 60 mg vs. 2 infusions of 60 mg over 24 hours)
Merlotti 2011	Randomised clinical study. Study without a comparison of interest. The study compared two regimens of neridronate (100 mg intravenous infusion for 2 consecutive days vs. 25 mg intramuscular infusion once a week for 2 months)
O'Doherty 1995	Not a randomised clinical study. Study without a comparison of interest. The study compared three doses of intravenous alendronate (2.5 mg, 5 mg and 10 mg daily) for 5 consecutive days
Pepersack 1994	Not a randomised clinical study. Study without a comparison of interest. The study compared one oral and four intravenous regimens of pamidronate (600 mg daily for 6 months, 40 mg daily for five days, 20 mg daily for 10 days, 10 mg daily for 4 days and a single dose of 10 mg)
Reginster 1988	Randomised clinical study. Study without a comparison of interest. The study compared three regimens of tiludronate (200 mg daily for 6 months, 400 mg daily for 6 months, 200 mg daily for 3 months and 400 mg daily for 3 additional months)
Reginster 1993	Randomised clinical study. Study without a comparison of interest. The study compared three regimens of tiludronate (600 mg, 800 mg and 1200 mg daily) for five days
Russell 1974	Not a randomised clinical study. Study without a comparison of interest. The study compared four doses of etidronate (1 mg, 5 mg, 10 mg and 20 mg) for 6 months and placebo
Siris 1980	Extension study (of Canfield 1977). Only participants from the Columbia Presbyterian Medical Center (1 of the 4 hospitals in the original trial) were included in the study. All participants were treated with etidronate
Stone 1990	Not a randomised clinical study. Study without a comparison of interest. The study compared three regimens of pamidronate (15 mg, 30 mg, or 45 mg infusions) at 6 week intervals
Vega 1994	Randomised clinical study. Study without a comparison of interest. The study compared seven regimens of pamidronate in two formulations (3 dose levels of oral capsules of pamidronate; 300 mg, 600 mg and 900 mg and four dose levels of oral tables of dimethyl pamidronate; 50 mg, 100 mg, 200 mg and 400 mg). Each dose was administered for 15 days